Skip to content
AnalystLens

IDEXX Laboratories 8-K Report, Executive Changes (Jan 13, 2026)

Reports
Leadership Changes·Regulation FD·Exhibits & Filings
Filing Date
Filed January 13, 2026
Period End
January 11, 2026
Security
IDXX
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Nov ’20Nov ’20
  2. Material agreement8-K · Oct ’22Oct ’22
  3. Leadership change8-K · Feb ’25Feb ’25

Summary

Summary of the 8-K filed January 13, 2026. Cited figures are marked; the original filing is the authoritative source.

On January 13, 2026, IDEXX Laboratories announced a planned CEO succession.

Jonathan (Jay) Mazelsky, President and CEO since 2019, will step down as CEO effective May 12, 2026, and move to Executive Chair of the Board. Michael (Mike) Erickson, PhD, currently EVP and General Manager of Global Point of Care Diagnostics and Telemedicine, will become President and CEO on that date and join the Board as a Class II Director. Mazelsky plans to retire from the company and the Board immediately after the May 2027 annual shareholder meeting, giving the two a roughly one-year overlap.

Lawrence D. Kingsley, the current independent Non-Executive Chair, will become independent Lead Director on the Transition Date. The filing is largely a planned, orderly succession rather than a response to performance problems, and the company frames it as the outcome of a formal Board succession planning process.

The filing does not disclose any change to guidance, financial results, or strategy. The main investor-relevant items are the compensation terms and the change-in-control protections. Erickson's base salary is $1,000,000a with a 120% target bonus, and he is expected to receive a 2026 long-term equity award with a target grant value of at least $7.8 million, split 50% stock options and 50% performance RSUs.

Mazelsky's Executive Chair salary is $1,150,000,b and he is expected to receive time-vesting RSUs with a target grant value of at least $8.275 million. Both agreements include severance and change-in-control provisions, which are standard for this type of transition.

For investors, the key questions are whether Erickson's continuity as a long-serving insider supports execution on the company's innovation-driven growth strategy, and whether the overlap period with Mazelsky reduces transition risk. The filing gives no indication of execution risk, though investors should watch for the company's plans for the strategy and any changes to its operating priorities once Erickson takes over in May 2026.

Key Highlights

  1. CEO transition: Jay Mazelsky steps down as President and CEO effective May 12, 2026, and becomes Executive Chair; Mike Erickson, PhD, succeeds him as President and CEO.
  2. Mazelsky retires from the Company and the Board immediately after the May 2027 annual shareholder meeting, providing roughly a one-year overlap for a smooth handover.
  3. Erickson, an IDEXX insider since 2011, joins the Board as a Class II Director; he currently leads Global Point of Care Diagnostics and Telemedicine.
  4. Erickson compensation: $1,000,000 base salary, 120% target bonus, and a 2026 long-term equity award with target value of at least $7.8 million (50% options, 50% performance RSUs).
  5. Mazelsky compensation: $1,150,000 annual base salary as Executive Chair, FY2026 target bonus on a blended 130%/100% basis, and a time-vesting RSU grant with target value of at least $8.275 million.
  6. Erickson's change-in-control agreement provides a lump sum of three times salary plus average bonus, three years of benefits continuation, and accelerated vesting of time-based equity on a qualifying termination within two years after a change in control.
  7. Lawrence D. Kingsley moves from independent Non-Executive Chair to independent Lead Director effective on the Transition Date.

Frequently Asked Questions

  1. When does the CEO transition take effect?

    The transition takes effect May 12, 2026. Erickson becomes President and CEO and joins the Board on that date, and Mazelsky becomes Executive Chair. Mazelsky plans to retire from the Company and the Board immediately after the May 2027 annual shareholder meeting.

  2. Why is the CEO changing, and does it signal any problems at IDEXX?

    The filing and press release describe the change as the result of the Board's succession planning process. Mazelsky has announced his intention to retire and will remain as Executive Chair to support the handover. The filing does not disclose any operational, financial, or performance problems behind the change.

  3. How is Mike Erickson compensated as CEO?

    Erickson's base salary is $1,000,000, with an annual bonus target of 120% of base salary. For fiscal 2026 he is expected to receive a long-term equity award with a target grant date value of at least $7.8 million, split 50% stock options and 50% performance RSUs, granted in February 2026 under the 2018 Stock Incentive Plan.

  4. What protections does Erickson have if he is terminated?

    If terminated without Cause after the Transition Date, Erickson receives two years of salary continuation, a lump-sum payment of the employer share of health benefit costs for two years, and two years of continued equity vesting, subject to a release of claims. Under his amended change-in-control agreement, a qualifying termination within two years after a change in control triggers a lump sum of three times salary plus average bonus, three years of benefits continuation, and immediate vesting of time-based equity awards.

  5. Does the transition change Mazelsky's role or pay, and what happens to Kingsley?

    Mazelsky becomes Executive Chair with a $1,150,000 base salary through his retirement date and a time-vesting RSU grant with target value of at least $8.275 million for 2026. He will not receive other cash or equity incentive payments for his Executive Chair service in fiscal 2027. Kingsley, the current independent Non-Executive Chair, becomes independent Lead Director on the Transition Date.